CAD106 targets a fragment of the ha

CAD106 targets a fragment of the harmful form of the beta amyloid peptide, the main component of the plaques found in the brains of people with Alzheimer's disease. In the Karolinska Institutet study, people with mild-to-moderate Alzheimer's developed protective antibodies against beta amyloid without any side effects, and the researchers want to carry out larger trials.